Genedx Holdings Corp. (WGS)
NASDAQ:WGS
Want to see WGS full AI Analyst Report?
WGS Stock Chart & Stats
$65.96
-$4.29(-4.42%)
At close: 4:00 PM EST
$65.96
-$4.29(-4.42%)
Day’s Range― - ―
52-Week Range$32.21 - $170.87
Previous CloseN/A
Volume338.68K
Average Volume (3M)1.41M
Market Cap
$2.04B
Enterprise Value$1.75B
Total Cash (Recent Filing)$170.69M
Total Debt (Recent Filing)$168.19M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 17, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding29,688,026
10 Day Avg. Volume1,137,662
30 Day Avg. Volume1,410,341
Financial Highlights & Ratios
PEG Ratio2.86
Price to Book (P/B)11.35
Price to Sales (P/S)8.18
P/FCF Ratio245.23
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue3.95
Enterprise Value/Gross Profit5.78
Enterprise Value/Ebitda-36.07
Forecast
1Y Price Target
$75.43Price Target Upside14.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.13
Revenue Forecast (FY)$478.38M
Bulls Say, Bears Say
Bulls Say
Proprietary Data MoatA large, proprietary dataset (>2.5M patients, >1M exomes/genomes, >8M phenotypic profiles) provides a durable competitive advantage for variant interpretation, payer evidence-building, and biopharma collaborations. This asset supports product differentiation and recurring revenue opportunities over multiple years.
Sustained Volume And Margin ExpansionRobust demand and improving unit economics—34% test volume growth and 27% exome/genome revenue growth with ~69% adjusted gross margin—indicate the core business is scaling with favorable mix toward higher-content, higher-margin tests. These trends underpin a credible pathway to sustained adjusted profitability.
Strengthened Commercial & Operational LeadershipLeadership hires and clear cost discipline—appointment of an experienced diagnostics executive (nearly three decades) into the president role plus a $25M OpEx recalibration and expanded sales coverage—improve execution capacity, commercial scale, and focus on profitable growth across specialty and expansion channels.
Bears Say
Deteriorating Cash GenerationA reversion to negative operating and free cash flow raises durable funding and execution risks. Persistent cash outflows hinder the company's ability to self-fund growth, increase reliance on external financing, and constrain reinvestment in commercialization or payer efforts until sustained profitability and cash conversion are restored.
Reimbursement & Mix HeadwindsStructural reimbursement gaps—genome ARR materially below exome and blended ARR short of expectations—reflect immature payer coverage and more complex revenue-cycle work. Improving ARR and collections requires multiple quarters of payer expansion and operational changes, limiting durable margin improvement near term.
Execution Issues & Asset ImpairmentMaterial non-core misses, a $31.3M Fabric impairment and a ~12% guidance reduction signal execution and portfolio prioritization failures. These events reduce near-term growth visibility, indicate past investments that failed to scale, and constrain management’s ability to invest freely while rebuilding reliable revenue streams.
GeneDx Holdings News
WGS FAQ
What was Genedx Holdings Corp.’s price range in the past 12 months?
Genedx Holdings Corp. lowest stock price was $32.21 and its highest was $170.87 in the past 12 months.
What is Genedx Holdings Corp.’s market cap?
Genedx Holdings Corp.’s market cap is $2.04B.
When is Genedx Holdings Corp.’s upcoming earnings report date?
Genedx Holdings Corp.’s upcoming earnings report date is Aug 17, 2026 which is in 52 days.
How were Genedx Holdings Corp.’s earnings last quarter?
Genedx Holdings Corp. released its earnings results on May 04, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.015 by -$0.265.
Is Genedx Holdings Corp. overvalued?
According to Wall Street analysts Genedx Holdings Corp.’s price is currently Undervalued.
Does Genedx Holdings Corp. pay dividends?
Genedx Holdings Corp. does not currently pay dividends.
What is Genedx Holdings Corp.’s EPS estimate?
Genedx Holdings Corp.’s EPS estimate is -0.19.
How many shares outstanding does Genedx Holdings Corp. have?
Genedx Holdings Corp. has 29,688,026 shares outstanding.
What happened to Genedx Holdings Corp.’s price movement after its last earnings report?
Genedx Holdings Corp. reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.015. Following the earnings report the stock price went down -49.198%.
Which hedge fund is a major shareholder of Genedx Holdings Corp.?
Currently, no hedge funds are holding shares in WGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GeneDx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.43 (14.36% Upside)
$75.43 (14.36% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 666.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $93.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.78%
12-Months-Change
Fundamentals
Return on Equity
-27.50%
Trailing 12-Months
Asset Growth
13.41%
Trailing 12-Months
Company Description
Genedx Holdings Corp.
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.
WGS Company Deck
WGS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong operational momentum (34% volume growth, 27% exome/genome revenue growth, healthy ~69% adjusted gross margin, large proprietary dataset, new commercial products and expanded sales coverage) tempered by near-term execution and mix challenges (approximately $12M revenue shortfall in Q1 driven by lower blended ARR and $6.5M non-core misses), a significant Fabric impairment (~$31.3M), and a 12% reduction to prior full-year revenue expectations. Management laid out concrete remediation actions — tighter channel/revenue-cycle management, cost recalibration ($25M OpEx reduction), and focused commercial execution — and provided updated guidance that emphasizes line-of-sight growth and a pathway back to adjusted profitability in 2026, with further ARR improvement expected over multiple quarters as payer coverage and collections improve.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$75.43
▲(14.36% Upside)
Technical Analysis
Evolent Health
―
10x Genomics
―
Certara
―
SOPHiA GENETICS
―
BrightSpring Health Services, Inc.
―
Ownership Overview
42.24% Insiders
24.60% Mutual Funds
17.89% Other Institutional Investors
2.11% Public Companies and
Individual Investors